S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
Is This Stock On Your Radar (Ad)
How to Find Penny Stocks to Invest and Trade
Can Cummins Power To A New High? 
Solar Industry at Start of Long Bull Run? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Solar Industry at Start of Long Bull Run? (Ad)
Stocks slip as worries about high rates weigh on Wall Street
Is Biotech Immunocore About To Make A 25% Price Move?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
Is This Stock On Your Radar (Ad)
How to Find Penny Stocks to Invest and Trade
Can Cummins Power To A New High? 
Solar Industry at Start of Long Bull Run? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Solar Industry at Start of Long Bull Run? (Ad)
Stocks slip as worries about high rates weigh on Wall Street
Is Biotech Immunocore About To Make A 25% Price Move?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
Is This Stock On Your Radar (Ad)
How to Find Penny Stocks to Invest and Trade
Can Cummins Power To A New High? 
Solar Industry at Start of Long Bull Run? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Solar Industry at Start of Long Bull Run? (Ad)
Stocks slip as worries about high rates weigh on Wall Street
Is Biotech Immunocore About To Make A 25% Price Move?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
Is This Stock On Your Radar (Ad)
How to Find Penny Stocks to Invest and Trade
Can Cummins Power To A New High? 
Solar Industry at Start of Long Bull Run? (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
Solar Industry at Start of Long Bull Run? (Ad)
Stocks slip as worries about high rates weigh on Wall Street
Is Biotech Immunocore About To Make A 25% Price Move?
NASDAQ:ALBO

Albireo Pharma - ALBO Stock Forecast, Price & News

$44.59
-0.36 (-0.80%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$44.38
$45.13
50-Day Range
$18.01
$44.95
52-Week Range
$16.02
$45.23
Volume
210,723 shs
Average Volume
821,303 shs
Market Capitalization
$923.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
7.6% Upside
$48.00 Price Target
Short Interest
Healthy
3.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.69
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$178,670 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.86) to ($6.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

585th out of 1,027 stocks

Pharmaceutical Preparations Industry

280th out of 500 stocks

ALBO stock logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock News Headlines

ALBO.PH - | Stock Price & Latest News | Reuters
Why These Two Biotech Stocks Blasted Higher This Week
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Expert Ratings for Albireo Pharma
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Albireo Announces 2022 SPARK Grant Winners
See More Headlines
Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Company Calendar

Last Earnings
11/04/2021
Today
2/07/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+7.6%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

Net Income
$-34,030,000.00
Net Margins
-228.51%
Pretax Margin
-235.11%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
19,273,000
Market Cap
$923.01 million
Optionable
Optionable
Beta
1.03

Social Links


Key Executives

  • Ronald H. W. Cooper
    President, Chief Executive Officer & Director
  • Simon John HarfordSimon John Harford
    Chief Financial Officer & Treasurer
  • Jan Peter Mattsson
    Chief Scientific Officer, Managing Director-Sweden
  • Joan Connolly
    Chief Technology Officer
  • Paul D. Streck
    Chief Medical Officer













ALBO Stock - Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares.
View ALBO analyst ratings
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month price objectives for Albireo Pharma's stock. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they predict the company's stock price to reach $48.00 in the next year. This suggests a possible upside of 7.6% from the stock's current price.
View analysts price targets for ALBO
or view top-rated stocks among Wall Street analysts.

How have ALBO shares performed in 2023?

Albireo Pharma's stock was trading at $21.61 on January 1st, 2023. Since then, ALBO shares have increased by 106.3% and is now trading at $44.59.
View the best growth stocks for 2023 here
.

When is Albireo Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ALBO earnings forecast
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to analysts' expectations of $22.33 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%. During the same period last year, the company earned ($1.96) earnings per share.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (6.58%), Rice Hall James & Associates LLC (2.48%), International Biotechnology Trust PLC (0.18%), Simplex Trading LLC (0.00%), Zurcher Kantonalbank Zurich Cantonalbank (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends
.

How do I buy shares of Albireo Pharma?

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $44.59.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $923.01 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does Albireo Pharma have?

The company employs 130 workers across the globe.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 2/7/2023 by MarketBeat.com Staff